Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
NASDAQ:PHAS

PhaseBio Pharmaceuticals - PHAS Stock Forecast, Price & News

$0.06
0.00 (0.00%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.98
52-Week Range
$0.07
$4.08
Volume
135,304 shs
Average Volume
848,888 shs
Market Capitalization
$2.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

PhaseBio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7,527.1% Upside
$4.50 Price Target
Short Interest
Bearish
5.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$267,616 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

PHAS stock logo

About PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

PhaseBio Files for Bankruptcy With Plans to Sell Assets
See More Headlines
Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Company Calendar

Last Earnings
11/10/2021
Today
11/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAS
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+7,527.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-131,070,000.00
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%

Debt

Sales & Book Value

Annual Sales
$10.83 million
Book Value
($1.93) per share

Miscellaneous

Free Float
44,922,000
Market Cap
$2.94 million
Optionable
Not Optionable
Beta
2.57

Key Executives

  • Jonathan P. Mow
    Chief Executive Officer & Director
  • John P. Sharp
    Chief Financial Officer
  • John S. Lee
    Chief Medical Officer
  • Kristopher L. Hanson
    Secretary, Senior VP & General Counsel
  • Susan E. Arnold
    Senior Vice President-Technical Operations













PHAS Stock - Frequently Asked Questions

Should I buy or sell PhaseBio Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares.
View PHAS analyst ratings
or view top-rated stocks.

What is PhaseBio Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 1 year price targets for PhaseBio Pharmaceuticals' stock. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 7,527.1% from the stock's current price.
View analysts price targets for PHAS
or view top-rated stocks among Wall Street analysts.

How have PHAS shares performed in 2022?

PhaseBio Pharmaceuticals' stock was trading at $2.61 at the beginning of the year. Since then, PHAS shares have decreased by 97.7% and is now trading at $0.0590.
View the best growth stocks for 2022 here
.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The business had revenue of $0.34 million for the quarter, compared to analysts' expectations of $2.67 million.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Resources Investment Advisors LLC. (0.34%). Insiders that own company stock include Clay Thorp, Edmund Harrigan, Enterprise Associates 13 L New and Glen Burkhardt.
View institutional ownership trends
.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $0.06.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $2.94 million and generates $10.83 million in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com.

This page (NASDAQ:PHAS) was last updated on 11/27/2022 by MarketBeat.com Staff